Serial Convalescent Plasma Infusions for the Initial COVID-19 Infections in the Appalachian Region of West Virginia
Open Access
- 1 January 2022
- journal article
- research article
- Published by SAGE Publications in Allergy & Rhinology
- Vol. 13
Abstract
Purpose: The rapid spread of SARS-CoV-2, the virus that is responsible for causing COVID-19, has presented the medical community with another example of when convalescent plasma (CP) is still used today. The ability to standardize CP at the onset of a pandemic is unlikely to exist in a reliable and uniformly reproducible way. We hypothesized that CP of unknown strength given in a serial manner will promote health and reduce mortality in those inflicted with COVID-19. Methods: Participants were given up to 8 CP-units depending on their condition upon entry into the study and their response. Results: 102 out of 117 participants were given CP. The earlier a participant received CP corelated with survival (p = 0.0004). The number of CP-units given, throughout all the clinical severities, was not significant with outcomes, p = 0.3947. A higher number of CP-units given to the severe/critical participants (without biological immunosuppressants or restrictive lung disease) did correlate with survival p = 0.0116 (2.8 vs. 2 units). Lower platelets on admission corelated with mortality. Platelet levels increase correlated with CP infusions p < 0.0001. Conclusion: This study supports the serial use of CP of unknown strength based on clinical response for those infected with COVID-19. The use of 3–4 units of CP was found to be statistically significant for survival for severe and critical participants without restrictive lung disease and chronic biological immunosuppression. Increased platelet levels after CP infusions supports that CP is promoting overall health regardless of outcomes.Keywords
This publication has 23 references indexed in Scilit:
- Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19JAMA, 2020
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent PlasmaJAMA, 2020
- Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in ChinaJAMA, 2020
- Convalescent plasma as a potential therapy for COVID-19The Lancet Infectious Diseases, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Use of Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios in COVID-19Journal of Clinical Medicine Research, 2020
- Integrated COVID-19 Convalescent Plasma Treatment and Antibody Research Program at a Single Academic Medical CenterSSRN Electronic Journal, 2020
- Organizing the Donation of Convalescent Plasma for a Therapeutic Clinical Trial on Ebola Virus Disease: The Experience in GuineaThe American Journal of Tropical Medicine and Hygiene, 2016
- THE USE OF CONVALESCENT HUMAN SERUM IN INFLUENZA PNEUMONIA—A PRELIMINARY REPORTAmerican Journal of Public Health, 1918
- EXPERIMENTAL POLIOMYELITIS IN MONKEYSEIGHTH NOTE: FURTHER CONTRIBUTIONS TO THE SUBJECTS OF IMMUNIZATION AND SERUM THERAPYJAMA, 1910